Probi Inkomsten in het verleden

Verleden criteriumcontroles 1/6

De winst van Probi is gedaald met een gemiddeld jaarlijks percentage van -32.7%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 7.7%. De inkomsten zijn daalde met een gemiddeld percentage van 1.6% per jaar. Het rendement op het eigen vermogen Probi bedraagt 0.8% en de nettomarge bedraagt 1.7%.

Belangrijke informatie

-32.7%

Groei van de winst

-32.7%

Groei van de winst per aandeel

Biotechs Groei van de industrie	0.7%
Inkomstengroei	-1.6%
Rendement op eigen vermogen	0.8%
Nettomarge	1.7%
Volgende winstupdate	28 Jan 2025

Recente prestatie-updates uit het verleden

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

Jul 24

Recent updates

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

Jul 24

There's No Escaping Probi AB (publ)'s (STO:PROB) Muted Revenues Despite A 43% Share Price Rise

Jun 26

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 19% Below Its Share Price

May 05

Is Probi AB (publ)'s (STO:PROB) Recent Price Movement Underpinned By Its Weak Fundamentals?

Mar 05

Here's Why I Think Probi (STO:PROB) Might Deserve Your Attention Today

Feb 15

Here's What Probi AB (publ)'s (STO:PROB) Shareholder Ownership Structure Looks Like

Jan 29

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 20% Below Its Share Price

Jan 11

Have Insiders Been Buying Probi AB (publ) (STO:PROB) Shares?

Dec 22

Has Probi AB (publ)'s (STO:PROB) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Dec 03

Opbrengsten en kosten

Hoe Probi geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

OM:PROB Opbrengsten, kosten en inkomsten (SEK Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	630	11	170	36
30 Jun 24	643	14	170	37
31 Mar 24	608	-1	174	37
31 Dec 23	628	17	172	36
30 Sep 23	616	14	176	39
30 Jun 23	605	20	174	38
31 Mar 23	635	46	168	39
31 Dec 22	618	41	167	38
30 Sep 22	644	73	159	36
30 Jun 22	658	79	155	38
31 Mar 22	642	75	147	37
31 Dec 21	658	83	143	37
30 Sep 21	673	79	140	39
30 Jun 21	709	93	144	37
31 Mar 21	731	105	144	37
31 Dec 20	717	93	150	36
30 Sep 20	699	97	149	33
30 Jun 20	645	85	144	32
31 Mar 20	646	88	153	33
31 Dec 19	626	86	151	31
30 Sep 19	623	84	154	30
30 Jun 19	650	90	157	31
31 Mar 19	623	81	150	31
31 Dec 18	604	76	147	33
30 Sep 18	561	53	139	35
30 Jun 18	525	34	139	34
31 Mar 18	544	29	139	35
31 Dec 17	612	69	138	37
30 Sep 17	687	98	147	41
30 Jun 17	643	117	138	41
31 Mar 17	544	118	122	40
31 Dec 16	443	102	103	37
30 Sep 16	286	74	53	54
30 Jun 16	248	60	49	48
31 Mar 16	234	54	53	38
31 Dec 15	216	49	57	31
30 Sep 15	220	52	82	0
30 Jun 15	205	46	76	0
31 Mar 15	178	39	67	0
31 Dec 14	135	22	60	0
30 Sep 14	122	19	58	0
30 Jun 14	109	16	56	0
31 Mar 14	104	15	55	0
31 Dec 13	104	15	55	0

Kwaliteitswinsten: PROB heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (1.7%) PROB } zijn lager dan vorig jaar (2.2%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van PROB is de afgelopen 5 jaar met 32.7% per jaar gedaald.

Versnelling van de groei: De winstgroei PROB is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.

Winst versus industrie: PROB had het afgelopen jaar een negatieve winstgroei ( -20.4% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Biotechs ( -20.8% ).

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 0.8% ) van PROB wordt als laag beschouwd.

Probi Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Third quarter 2024 earnings released: EPS: kr0.31 (vs kr0.56 in 3Q 2023)

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

Second quarter 2024 earnings released: EPS: kr0.71 (vs kr0.55 loss in 2Q 2023)

Full year 2023 earnings: EPS exceeds analyst expectations

Probi AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Full year 2023 earnings: EPS exceeds analyst expectations

Recent updates

Probi AB Launches Clinically-Supported Probiotic Solution for Metabolic Health at SupplySide West 2024

Third quarter 2024 earnings released: EPS: kr0.31 (vs kr0.56 in 3Q 2023)

Probi AB (Publ) Launches Probi Sense

New minor risk - Share price stability

Now 21% undervalued

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

Second quarter 2024 earnings released: EPS: kr0.71 (vs kr0.55 loss in 2Q 2023)

Probi AB (publ) Strengthens the Gut-Brain Offering with New Study in Older Adults

There's No Escaping Probi AB (publ)'s (STO:PROB) Muted Revenues Despite A 43% Share Price Rise

Probi AB (publ) Approves Election of Stephanie Blum Sperisen as Board Member

Now 22% undervalued

Now 22% undervalued

Full year 2023 earnings: EPS exceeds analyst expectations

Now 21% undervalued

Dividend of kr1.30 announced

Now 21% undervalued after recent price drop

Probi AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Full year 2023 earnings: EPS exceeds analyst expectations

Probi AB (Publ) Proposes Dividend for the Fiscal Year 2023

Probi AB (publ) to Report Q3, 2024 Results on Oct 22, 2024

Probi AB (publ), Annual General Meeting, May 07, 2024

Third quarter 2023 earnings released: EPS: kr0.56 (vs kr1.09 in 3Q 2022)

Probi AB (Publ) Appoints Per Lindblad as New CFO, Effective from 1st of November, 2023

Probi Launches Two New Concepts Together with Clasado Biosciences at Supply Side West

Second quarter 2023 earnings released: kr0.55 loss per share (vs kr1.75 profit in 2Q 2022)

Probi AB (Publ) Announces Resignation of Henrik Lundkvist as Chief Financial Officer

Insufficient new directors

Upcoming dividend of kr1.30 per share at 0.7% yield

Full year 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (publ) to Report Fiscal Year 2022 Final Results on Apr 04, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (Publ) Proposes Dividend for the 2022 Financial Year, Payable on May 11, 2023

Now 24% undervalued after recent price drop

Now 20% undervalued after recent price drop

Probi AB (publ) to Report Q2, 2023 Results on Jul 18, 2023

Now 21% undervalued after recent price drop

Probi AB (publ) Announces Management Changes

Now 25% undervalued after recent price drop

Probi Probiotics Reduce Gut Problems in Connection with Cancer Radiotherapy

Now 21% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (publ) Provides Earnings Guidance for the Third Quarter of 2022

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Probi AB (Publ) Approves Dividend for the Financial Year 2021

Chief Executive Officer recently bought kr409k worth of stock

Upcoming dividend of kr1.30 per share

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Probi AB (Publ) Proposes Dividend, Payable on 12 May 2022

Now 23% undervalued after recent price drop

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Probi AB (Publ) Proposes Dividend for the Year 2021

Third quarter 2021 earnings released: EPS kr1.62 (vs kr2.91 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Should You Be Adding Probi (STO:PROB) To Your Watchlist Today?

Estimating The Intrinsic Value Of Probi AB (publ) (STO:PROB)

Consensus EPS estimates fall to kr8.37

Second quarter 2021 earnings released: EPS kr1.39 (vs kr2.37 in 2Q 2020)

Investor sentiment improved over the past week

Is Now The Time To Put Probi (STO:PROB) On Your Watchlist?

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 19% Below Its Share Price

Upcoming dividend of kr1.10 per share

Price target increased to kr505

Full year 2020 earnings released: EPS kr8.14 (vs kr7.54 in FY 2019)

Probi AB (publ) Announces Three Years Collaboration with La Trobe University